655 related articles for article (PubMed ID: 34402426)
41. SARS-CoV-2-Encoded MiRNAs Inhibit Host Type I Interferon Pathway and Mediate Allelic Differential Expression of Susceptible Gene.
Zhu Y; Zhang Z; Song J; Qian W; Gu X; Yang C; Shen N; Xue F; Tang Y
Front Immunol; 2021; 12():767726. PubMed ID: 35003084
[TBL] [Abstract][Full Text] [Related]
42. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
[TBL] [Abstract][Full Text] [Related]
43. Conserved Genomic Terminals of SARS-CoV-2 as Coevolving Functional Elements and Potential Therapeutic Targets.
Chan AP; Choi Y; Schork NJ
mSphere; 2020 Nov; 5(6):. PubMed ID: 33239366
[TBL] [Abstract][Full Text] [Related]
44. Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity.
Zheng J; Zhang Y; Zhao H; Liu Y; Baird D; Karim MA; Ghoussaini M; Schwartzentruber J; Dunham I; Elsworth B; Roberts K; Compton H; Miller-Molloy F; Liu X; Wang L; Zhang H; Smith GD; Gaunt TR
EBioMedicine; 2022 Jul; 81():104112. PubMed ID: 35772218
[TBL] [Abstract][Full Text] [Related]
45. Mapping the human genetic architecture of COVID-19.
COVID-19 Host Genetics Initiative
Nature; 2021 Dec; 600(7889):472-477. PubMed ID: 34237774
[TBL] [Abstract][Full Text] [Related]
46. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
47. Endomembrane targeting of human OAS1 p46 augments antiviral activity.
Soveg FW; Schwerk J; Gokhale NS; Cerosaletti K; Smith JR; Pairo-Castineira E; Kell AM; Forero A; Zaver SA; Esser-Nobis K; Roby JA; Hsiang TY; Ozarkar S; Clingan JM; McAnarney ET; Stone AE; Malhotra U; Speake C; Perez J; Balu C; Allenspach EJ; Hyde JL; Menachery VD; Sarkar SN; Woodward JJ; Stetson DB; Baillie JK; Buckner JH; Gale M; Savan R
Elife; 2021 Aug; 10():. PubMed ID: 34342578
[TBL] [Abstract][Full Text] [Related]
48. Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19.
Corley MJ; Pang APS; Dody K; Mudd PA; Patterson BK; Seethamraju H; Bram Y; Peluso MJ; Torres L; Iyer NS; Premeaux TA; Yeung ST; Chandar V; Borczuk A; Schwartz RE; Henrich TJ; Deeks SG; Sacha JB; Ndhlovu LC
J Leukoc Biol; 2021 Jul; 110(1):21-26. PubMed ID: 33464637
[TBL] [Abstract][Full Text] [Related]
49. The Immune Response of
Gajate-Arenas M; Fricke-Galindo I; García-Pérez O; Domínguez-de-Barros A; Pérez-Rubio G; Dorta-Guerra R; Buendía-Roldán I; Chávez-Galán L; Lorenzo-Morales J; Falfán-Valencia R; Córdoba-Lanús E
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731851
[TBL] [Abstract][Full Text] [Related]
50. C-type Lectin CD209L/L-SIGN and CD209/DC-SIGN: Cell Adhesion Molecules Turned to Pathogen Recognition Receptors.
Rahimi N
Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33375175
[TBL] [Abstract][Full Text] [Related]
51. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
52. Modifiable lifestyle factors and severe COVID-19 risk: a Mendelian randomisation study.
Li S; Hua X
BMC Med Genomics; 2021 Feb; 14(1):38. PubMed ID: 33536004
[TBL] [Abstract][Full Text] [Related]
53. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
54. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
55. A genome-wide functional genomics approach uncovers genetic determinants of immune phenotypes in type 1 diabetes.
Chu X; Janssen AWM; Koenen H; Chang L; He X; Joosten I; Stienstra R; Kuijpers Y; Wijmenga C; Xu CJ; Netea MG; Tack CJ; Li Y
Elife; 2022 May; 11():. PubMed ID: 35638288
[TBL] [Abstract][Full Text] [Related]
56. Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.
Grolmusz VK; Bozsik A; Papp J; Patócs A
Front Immunol; 2021; 12():653489. PubMed ID: 33763088
[TBL] [Abstract][Full Text] [Related]
57. An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients.
Gonçalves BP; Hall M; Jassat W; Balan V; Murthy S; Kartsonaki C; Semple MG; Rojek A; Baruch J; Reyes LF; Dasgupta A; Dunning J; Citarella BW; Pritchard M; Martín-Quiros A; Sili U; Baillie JK; Aryal D; Arabi Y; Rashan A; Angheben A; Caoili J; Carrier FM; Harrison EM; Gómez-Junyent J; Figueiredo-Mello C; Douglas JJ; Mat Nor MB; Chow YP; Wong XC; Bertagnolio S; Thwin SS; Streinu-Cercel A; Salazar L; Rishu A; Rangappa R; Ong DSY; Hashmi M; Carson G; Diaz J; Fowler R; Kraemer MUG; Wils EJ; Horby P; Merson L; Olliaro PL;
Elife; 2022 Oct; 11():. PubMed ID: 36197074
[TBL] [Abstract][Full Text] [Related]
58. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.
Rao S; Lau A; So HC
Diabetes Care; 2020 Jul; 43(7):1416-1426. PubMed ID: 32430459
[TBL] [Abstract][Full Text] [Related]
59. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
60. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
